samedan logo
 
 
spacer
home > about us
Samedan Ltd. Pharmaceutical Publishers

Specialist pharmaceutical publisher Samedan Ltd is a dynamic, forward-thinking company, enjoying year-on-year growth with its five market-leading titles for industry professionals: European Pharmaceutical Contractor, Pharmaceutical Manufacturing and Packing Sourcer, European Biopharmaceutical Review, Innovations in Pharmaceutical Technology, and International Clinical Trials.

In 2013, the company extended its range with the acquisition of the Pharmafile portfolio, consisting of Pharmafocus newspaper, www.pharmafile.com, and Pharmafile directory. The London-based company has been producing a wide range of magazines for the global pharmaceutical arena since 1996, covering a wide range of hot topics including R&D, clinical trials, cutting-edge technology, manufacture, packaging, logistics, regulations, and industry insight.

Located in an idyllic region synonymous with culture and quality, the Alpine village of Samedan is renowned for its tradition of hospitality and shares many of its ideals with the company it inspired. Samedan hopes to develop its ties with the industry further still and maintains a fresh vision for the future.

spacer

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

News and Press Releases

LYNPARZA (olaparib) Plus Abiraterone Approved in the US for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck & Co., Incís, known as MSD outside the US and Canada, LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement